What’s Next for Neovascular Retinal Diseases? Preparing Patients for Impending Treatment Advances

What’s Next for Neovascular Retinal Diseases? Preparing Patients for Impending Treatment Advances is organized by Paradigm Medical Communications, LLC. 

Release Date: December 22, 2021
Expiration Date: December 22, 2022

Description:
Treatment of neovascular retinal diseases with intravitreal anti-vascular endothelial growth factor (VEGF), the long-running standard of care, is limited by a need for frequent repeat injections to derive optimal visual outcomes. The high treatment burden is associated with undertreatment (and, consequently, suboptimal visual outcomes) in the real world versus clinical trials. Innovative agents and delivery devices have the potential to upend onerous treatment paradigms while maintaining (and possibly even enhancing) efficacy. This educational initiative will outline the science behind novel agents and delivery modes that are poised to revolutionize the management of a variety of neovascular retinal diseases, so comprehensive ophthalmologists are better prepared to counsel patients about (and direct them toward) these groundbreaking treatment options.

Learning Objectives:
Upon completion of this activity, participants should be able to:
• Identify components of the angiopoietin (Ang)/Tie2 pathway that affect vascular stability, contributing to the pathophysiology of neovascular retinal diseases
• Assess the safety and efficacy of novel neovascular retinal disease treatments and modes of delivery
• Recognize key points for patient education regarding characteristics of new and emerging options for the treatment of neovascular retinal diseases, such as procedures, benefits, and risks